Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 86 The United Laboratories International Holdings Limited Annual Report 2025 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (a) Segment revenue and results (Continued) Note: During the year ended 31 December 2025, the Group entered into an exclusive license agreement (the “Exclusive License Agreement”) with a customer (the “Licensee”) for its patented intellectual property (the “Patented Intellectual Property”). Under the Exclusive License Agreement, the Licensee will obtain worldwide rights (excluding China mainland, the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan) (the “Territory”) to develop, manufacture and commercialise the Patented Intellectual Property. Under the Exclusive License Agreement and subject to the terms and conditions thereof, the Group is eligible to receive an upfront payment, potential milestone payments subject to the achievement of certain development and sales milestone and royalties based on annual net sales in the Territory. During the year ended 31 December 2025, an upfront payment of RMB1,442,210,000 was recognised as revenue as the Licensee obtained rights to access the underlying patented intellectual property.